C. García‐Barroso

发表

Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice

C. Alberini, C. Mulle, G. González-Aseguinolaza, 2014, EMBO molecular medicine.

Phosphodiesterases as therapeutic targets for Alzheimer's disease.

R. Franco, J. Oyarzábal, M. Cuadrado-Tejedor, 2012, ACS chemical neuroscience.

Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease

R. Franco, C. García-Barroso, A. García-Osta, 2011, British journal of pharmacology.

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

G. Perea, R. Franco, O. Rabal, 2017, Neuropsychopharmacology.

Multitarget Approach for the Treatment of Alzheimer`s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) covering diverse selectivity profiles.

O. Rabal, J. Oyarzábal, A. Pineda-Lucena, 2019, ACS chemical neuroscience.

Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2018, ACS chemical neuroscience.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2018, European journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2016, Journal of medicinal chemistry.

Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD

J. Lanciego, R. Franco, J. Oyarzábal, 2013, Neuropharmacology.

Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease

O. Rabal, J. Oyarzábal, V. Segura, 2019, Front. Aging Neurosci..

Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

G. Perea, R. Franco, O. Rabal, 2015, Clinical Epigenetics.

Decreased levels of guanosine 3′, 5′‐monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

R. Franco, J. Oyarzábal, A. Cedazo-Mínguez, 2015, Neuropathology and applied neurobiology.